Search research articles
Contact Us
Filters
Showing results (351-360 of 501) with videos related to
Page
of 51
Sort By:
Journal of Translational Medicine
|
November 7, 2015
Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
Lisa Zimmer, Thomas K Eigentler, Felix Kiecker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 25, 2012
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis
Benjamin Weide, Henning Zelba, Evelyna Derhovanessian, et al.
Journal for Immunotherapy of Cancer
|
July 14, 2019
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study
Andrea Forschner, Florian Battke, Dirk Hadaschik, et al.
The Journal of Investigative Dermatology
|
October 15, 2010
The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells
Heike Niessner, Daniela Beck, Tobias Sinnberg, et al.
Journal of Leukocyte Biology
|
January 23, 2020
Pitfalls in the characterization of circulating and tissue-resident human γδ T cells
Nicola Beucke, Daniela Wesch, Hans-Heinrich Oberg, et al.
Journal for Immunotherapy of Cancer
|
December 7, 2019
Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies
Nikolaus B Wagner, Benjamin Weide, Mirko Gries, et al.
Plos One
|
October 2, 2015
Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
Joanna Mangana, Phil F Cheng, Katja Schindler, et al.
International Journal of Cancer
|
May 29, 2015
Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma
Nikolaus B Wagner, Benjamin Weide, Maike Reith, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
September 9, 2016
Mitoserate beim primären Melanom: Interobserver- und Intraobserver-Reproduzierbarkeit am HE-Schnitt und in der Immunhistologie
Claus Garbe, Thomas K Eigentler, Jürgen Bauer, et al.
JCI Insight
|
October 4, 2019
Targeting tumor-resident mast cells for effective anti-melanoma immune responses
Susanne Kaesler, Florian Wölbing, Wolfgang Eberhard Kempf, et al.
Page
of 51
Search research articles
Search
Showing results (351-360 of 501) with videos related to
Sort By:
Page
of 51
Journal of Translational Medicine
|
November 7, 2015
Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
Lisa Zimmer, Thomas K Eigentler, Felix Kiecker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 25, 2012
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis
Benjamin Weide, Henning Zelba, Evelyna Derhovanessian, et al.
Journal for Immunotherapy of Cancer
|
July 14, 2019
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study
Andrea Forschner, Florian Battke, Dirk Hadaschik, et al.
The Journal of Investigative Dermatology
|
October 15, 2010
The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells
Heike Niessner, Daniela Beck, Tobias Sinnberg, et al.
Journal of Leukocyte Biology
|
January 23, 2020
Pitfalls in the characterization of circulating and tissue-resident human γδ T cells
Nicola Beucke, Daniela Wesch, Hans-Heinrich Oberg, et al.
Journal for Immunotherapy of Cancer
|
December 7, 2019
Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies
Nikolaus B Wagner, Benjamin Weide, Mirko Gries, et al.
Plos One
|
October 2, 2015
Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
Joanna Mangana, Phil F Cheng, Katja Schindler, et al.
International Journal of Cancer
|
May 29, 2015
Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma
Nikolaus B Wagner, Benjamin Weide, Maike Reith, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
September 9, 2016
Mitoserate beim primären Melanom: Interobserver- und Intraobserver-Reproduzierbarkeit am HE-Schnitt und in der Immunhistologie
Claus Garbe, Thomas K Eigentler, Jürgen Bauer, et al.
JCI Insight
|
October 4, 2019
Targeting tumor-resident mast cells for effective anti-melanoma immune responses
Susanne Kaesler, Florian Wölbing, Wolfgang Eberhard Kempf, et al.
Page
of 51